SMT201300004B - Fase precorritrice e sua utilizzazione per preparare il sale di magnesio tetraidrato di un enantiomero di omeprazolo - Google Patents
Fase precorritrice e sua utilizzazione per preparare il sale di magnesio tetraidrato di un enantiomero di omeprazoloInfo
- Publication number
- SMT201300004B SMT201300004B SM201300004T SM201300004T SMT201300004B SM T201300004 B SMT201300004 B SM T201300004B SM 201300004 T SM201300004 T SM 201300004T SM 201300004 T SM201300004 T SM 201300004T SM T201300004 B SMT201300004 B SM T201300004B
- Authority
- SM
- San Marino
- Prior art keywords
- prepare
- precursor phase
- tetrahydrate salt
- omeprazole enantiomer
- magnesium tetrahydrate
- Prior art date
Links
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical class N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title 1
- NZHDAMQFAJCLLC-UHFFFAOYSA-N magnesium;tetrahydrate Chemical compound O.O.O.O.[Mg] NZHDAMQFAJCLLC-UHFFFAOYSA-N 0.000 title 1
- 239000002243 precursor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009003954A DE102009003954A1 (de) | 2009-01-07 | 2009-01-07 | Pyridazinonderivate |
| PCT/EP2009/008840 WO2010078910A1 (de) | 2009-01-07 | 2009-12-10 | Pyridazinonderivate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201300004B true SMT201300004B (it) | 2013-03-08 |
Family
ID=41719075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201300004T SMT201300004B (it) | 2009-01-07 | 2013-01-09 | Fase precorritrice e sua utilizzazione per preparare il sale di magnesio tetraidrato di un enantiomero di omeprazolo |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8853211B2 (pl) |
| EP (1) | EP2373644B1 (pl) |
| JP (1) | JP2012514613A (pl) |
| KR (1) | KR101674695B1 (pl) |
| CN (1) | CN102272125B (pl) |
| AR (1) | AR075122A1 (pl) |
| AU (1) | AU2009336852B2 (pl) |
| BR (1) | BRPI0923913B1 (pl) |
| CA (1) | CA2748911C (pl) |
| CY (1) | CY1113698T1 (pl) |
| DE (1) | DE102009003954A1 (pl) |
| DK (1) | DK2373644T3 (pl) |
| EA (1) | EA019322B1 (pl) |
| ES (1) | ES2396301T3 (pl) |
| HR (1) | HRP20120979T1 (pl) |
| IL (1) | IL213828A (pl) |
| MX (1) | MX2011007165A (pl) |
| PL (1) | PL2373644T3 (pl) |
| PT (1) | PT2373644E (pl) |
| SG (1) | SG172421A1 (pl) |
| SI (1) | SI2373644T1 (pl) |
| SM (1) | SMT201300004B (pl) |
| WO (1) | WO2010078910A1 (pl) |
| ZA (1) | ZA201105780B (pl) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009003954A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009004061A1 (de) * | 2009-01-08 | 2010-07-15 | Merck Patent Gmbh | Pyridazinonderivate |
| CN102731409A (zh) * | 2011-04-08 | 2012-10-17 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物，其药物组合物、制备方法及用途 |
| WO2017108569A1 (en) | 2015-12-22 | 2017-06-29 | Syngenta Participations Ag | Pesticidally active pyrazole derivatives |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| KR102476708B1 (ko) | 2017-11-01 | 2022-12-09 | 삼성전자주식회사 | 광학 필터, 및 이를 포함하는 카메라 모듈 및 전자 장치 |
| KR102673362B1 (ko) * | 2018-03-27 | 2024-06-05 | 삼성전자주식회사 | 근적외선 흡수 필름, 광학 필터 및 전자 장치 |
| CN108752322A (zh) * | 2018-09-12 | 2018-11-06 | 广州新民培林医药科技有限公司 | 一种新型Tepotinib衍生物和制备方法及其在抗肿瘤药物中的应用 |
| US12404260B2 (en) | 2019-04-11 | 2025-09-02 | Janssen Pharmaceutica Nv | Pyridine rings containing derivatives as MALT1 inhibitors |
| CN115583939A (zh) * | 2022-11-04 | 2023-01-10 | 苏州莱安医药化学技术有限公司 | 一种特泊替尼中间体的合成方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5795964A (en) | 1980-12-04 | 1982-06-15 | Morishita Seiyaku Kk | Preparation of 2-substituted-3(2h)-pyridazinone derivative |
| US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| AU691673B2 (en) | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| CA2242425C (en) | 1996-02-13 | 2006-07-18 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| NZ331191A (en) | 1996-03-05 | 2000-03-27 | Zeneca Ltd | 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| BR9813998A (pt) | 1997-11-19 | 2000-09-26 | Kowa Co | Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| KR20030014425A (ko) | 2000-07-07 | 2003-02-17 | 앤지오젠 파마슈티칼스 리미티드 | 혈관 손상제인 콜치놀 유도체 |
| EE200300015A (et) | 2000-07-07 | 2004-10-15 | Angiogene Pharmaceuticals Limited | Kolhinooli derivaadid kui angiogeneesi inhibiitorid |
| MXPA04003668A (es) | 2001-10-31 | 2004-07-22 | Merck Patent Gmbh | Inhibidores de fosfodiesteresa de tipo 4 y usos de los mismos. |
| DE102005057924A1 (de) | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE602006018354D1 (de) | 2005-12-05 | 2010-12-30 | Pfizer Prod Inc | Verfahren zur behandlung von abnormalem zellwachstum |
| DE102006037478A1 (de) | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| US8340070B2 (en) * | 2006-10-03 | 2012-12-25 | Qualcomm Incorporated | Resource partitioning for wireless communication systems |
| DE102007025718A1 (de) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007025717A1 (de) * | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| DE102007032507A1 (de) * | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007061963A1 (de) | 2007-12-21 | 2009-06-25 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102008062826A1 (de) * | 2008-12-23 | 2010-07-01 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102009003954A1 (de) * | 2009-01-07 | 2010-07-08 | Merck Patent Gmbh | Pyridazinonderivate |
-
2009
- 2009-01-07 DE DE102009003954A patent/DE102009003954A1/de not_active Withdrawn
- 2009-12-10 PT PT97934673T patent/PT2373644E/pt unknown
- 2009-12-10 SI SI200930471T patent/SI2373644T1/sl unknown
- 2009-12-10 EA EA201101041A patent/EA019322B1/ru not_active IP Right Cessation
- 2009-12-10 CA CA2748911A patent/CA2748911C/en active Active
- 2009-12-10 ES ES09793467T patent/ES2396301T3/es active Active
- 2009-12-10 SG SG2011047511A patent/SG172421A1/en unknown
- 2009-12-10 JP JP2011544798A patent/JP2012514613A/ja active Pending
- 2009-12-10 KR KR1020117017551A patent/KR101674695B1/ko not_active Expired - Fee Related
- 2009-12-10 WO PCT/EP2009/008840 patent/WO2010078910A1/de not_active Ceased
- 2009-12-10 PL PL09793467T patent/PL2373644T3/pl unknown
- 2009-12-10 DK DK09793467.3T patent/DK2373644T3/da active
- 2009-12-10 BR BRPI0923913-8A patent/BRPI0923913B1/pt not_active IP Right Cessation
- 2009-12-10 EP EP09793467A patent/EP2373644B1/de active Active
- 2009-12-10 AU AU2009336852A patent/AU2009336852B2/en not_active Ceased
- 2009-12-10 HR HRP20120979AT patent/HRP20120979T1/hr unknown
- 2009-12-10 US US13/142,861 patent/US8853211B2/en active Active
- 2009-12-10 CN CN200980153447.XA patent/CN102272125B/zh not_active Expired - Fee Related
- 2009-12-10 MX MX2011007165A patent/MX2011007165A/es active IP Right Grant
-
2010
- 2010-01-06 AR ARP100100014A patent/AR075122A1/es active IP Right Grant
-
2011
- 2011-06-28 IL IL213828A patent/IL213828A/en not_active IP Right Cessation
- 2011-08-05 ZA ZA2011/05780A patent/ZA201105780B/en unknown
-
2012
- 2012-12-07 CY CY20121101192T patent/CY1113698T1/el unknown
-
2013
- 2013-01-09 SM SM201300004T patent/SMT201300004B/xx unknown
-
2014
- 2014-01-31 US US14/169,891 patent/US9376426B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201600184B (it) | Sale di meglumina di 6-fluoro-3-idrossi-2-pirazincarbossammide | |
| SMT201300008B (it) | Fase precorritrice e sua utilizzazione per preparare il sale di magnesio tetraidrato di un enantiomero di omeprazolo | |
| EP2649517A4 (en) | Fast computer startup | |
| SMT201600370B (it) | Complessi chelati di oligonucleotidi | |
| SMT201600072B (it) | Sale sodico di 6-fluoro-3-idrossi-2-pirazina carbossammide | |
| IL245328A0 (en) | Pharmaceutical composition | |
| ZA201104977B (en) | Removal of acid mists | |
| BR112013013663A2 (pt) | ácidos 1-benzilcicloalquilcarboxílicos substituídos e sua utilização | |
| UA21334S (uk) | Цукерка | |
| EP2594246A4 (en) | LIQUID COSMETICS | |
| EP2768987A4 (en) | NON-INVASIVE BIOREACTOR MONITORING | |
| EP2609107C0 (en) | PROCESS FOR THE SYNTHESIS OF OLIGORIBONUCLEOTIDES | |
| EP2689772A4 (en) | COSMETICS SOLID | |
| IL231262A0 (en) | A system for non-invasive testing of liver function | |
| AP2013006971A0 (en) | New form of administration of enkephalinase inhibitor | |
| EP2609209C0 (en) | COMPOUND SELECTION IN DRUG RESEARCH | |
| FR2955782B1 (fr) | Extraction solide / liquide | |
| IT1403035B1 (it) | Cristallizzatore per colata continua | |
| SMT201200060B (it) | Fase precorritrice e sua utilizzazione per preparare il sale di magnesio tetraidrato di un enantiomero di omeprazolo | |
| EP2736516A4 (en) | SUMOYLATION OF SERCA2A AND CARDIOVASCULAR DISEASES | |
| EP2578161A4 (en) | ULTRASOUND DEVICE | |
| SMT201500035B (it) | Sintesi di aliskiren | |
| BR112013013033A2 (pt) | preparação de produtos de tempero | |
| EP2593096A4 (en) | DICLOFENAC SALT OF TRAMADOL | |
| FI20106249L (fi) | Kertakäyttöinen sydämen sykkeenilmaisin |